Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis [PDF]
Antimicrobial Agents and Chemotherapy, 2019 There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium. Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of ...
Sondus Alkhazraji +8 more
semanticscholar +5 more sources
Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in ...
Teclegiorgis Gebremariam +6 more
semanticscholar +6 more sources
1282. Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In vitro Activity Against Members of the Fusarium oxysporum and Fusarium solani Species Complexes [PDF]
Open Forum Infectious Diseases, 2020 We evaluated the in vitro activity of manogepix against Fusarium oxysporum and Fusarium solani species complex (FOSC and FSSC, respectively) isolates per CLSI document M38 broth microdilution methods.
Hamid Badali +9 more
semanticscholar +3 more sources
147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial [PDF]
Open Forum Infectious Diseases, 2020 Background Fosmanogepix (FMGX) is a first-in-class antifungal agent, with a unique MOA targeting the fungal enzyme Gwt1, that has broad-spectrum activity against both yeasts, molds, and dimorphic fungi, including fungi resistant to other antifungal ...
Peter G. Pappas +15 more
semanticscholar +4 more sources
1954. In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis [PDF]
Open Forum Infectious Diseases, 2019 Background Candida auris is an emerging pathogen associated with antifungal resistance and high mortality. The novel antifungal manogepix (APX001A) prevents glycosylphosphatidylinositol-anchored protein maturation through inhibition of the inositol ...
Nathan P. Wiederhold +7 more
semanticscholar +3 more sources
Multi-Drug Resistant Fusariosis Treated with Fosmanogepix in a Lung Transplant Patient [PDF]
The Journal of Heart and Lung TransplantationGordon D. Wu +3 more
semanticscholar +3 more sources
Successful treatment of a resistant invasive disseminated Fusarium infection in an immunocompetent patient [PDF]
Medical Mycology Case ReportsFusariosis is a severe fungal infection associated with high mortality rates and an increasing incidence. However, its treatment remains challenging due to the frequent resistance of Fusarium species to conventional antifungal therapies.
Frantzeska Frantzeskaki +5 more
doaj +2 more sources
JHLT OpenNon-Aspergillus molds, including Mucorales, Scedosporium, Lomentospora, and Fusarium species, are a significant cause of morbidity and mortality in heart and lung transplant recipients.
Emily M. Eichenberger, MD, MHS +2 more
doaj +2 more sources
726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection [PDF]
Open Forum Infectious Diseases, 2019 Background Mucormycosis is a life-threatening infection that predominantly occurs in immunocompromised hosts. The antifungal APX001A (manogepix) inhibits Gwt1, an enzyme required for the conserved glycosylphosphatidyl inositol (GPI) post-translational ...
Teklegiorgis Gebremariam +6 more
openalex +2 more sources
Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm [PDF]
DiagnosticsInvasive pulmonary aspergillosis (IPA), traditionally associated with severe immunosuppression and neutropenia, is increasingly reported among non-neutropenic patients.
Rocco Morena +3 more
doaj +2 more sources